Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2005

View Archived Issues

Ligand updates progress of Targretin SPIRIT I and II trials

GB Therapeutics acquires CHF-1512 for Parkinson's disease

New phase III study investigates telavancin for hospital-acquired pneumonia

StaphVAX MAA accepted for review in Europe

FDA clears phase I trials to begin with human hookworm vaccine

LL-2113AD shows promise as add-on therapy for type 2 diabetes

First data on the benefits of letrozole as adjuvant therapy for early breast cancer

StreptAvax vaccine induces immune response to streptococcal antigens in healthy volunteers

Cytotoxic drugs reported to increase the antitumor effects of gene vaccines in a breast cancer model

Good safety profile found for KUR-1246 in pregnant sheep

Aradigm closes restructured licensing agreement with Novo Nordisk

Phenoxodiol receives fast track status for hormone-refractory prostate cancer

Norditropin NordiFlex now available in U.S.

Enrollment completed in phase III psoriasis trial for ISA-247

Pivotal study evaluates Acapodene for prostate cancer prevention

AL-108 enters phase I trials for Alzheimer's disease

UroGene to sell to Pierre Fabre uro-oncology programs, research platform

iNOS inhibitor, GW-274150, is protective in experimental colitis

New title added to the Drug R&D Backgrounders topic list - Scleroderma

Bemiparin is effective in a mouse asthma model

Novartis researchers claim PPAR modulators

Pfizer team describes novel series of PPARalpha activators

Lysophospholipid EDG receptor agonists disclosed in patents

Small-particle suspensions of anticonvulsant, antidementia and immunosuppressive agents

New combinations comprising modafinil reported by Cephalon

Kissei prepares and tests new agents for hyperuricemia

A novel series of immunosuppressants described in patent literature

Further data on use of Rho kinase inhibitor Y-27632 in hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...